Publications
- Highlighted Item:
- Publisher:
- Publication Date:
- Reference:
- DOI:
- PMID:
- Publication Type:Presentation
- Scientific Area:
- Endpoint:
- Industry Type:
Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Recording
Guest speaker, David Jones, Expert Pharmaco-Toxicologist at MHRA, gave this presentation as part of session 3 of Lhasa's 2020 AOP themed virtual symposium.
The session title was 'The potential utility of AOPs in the future of regulatory decision-making' and was the third in a series of 4 webinars that made up the symposium.
This publication is a recording of David's presentation slides.
